Resources

We are committed to providing support for you. Click on any of the links below to find out more information.

Contact

Please click here for more information on how to contact EUSA Pharma for general inquiries regarding Erwinaze (asparaginase Erwinia chrysanthemi) in the US.

CME grant

For more information on what we need in order to review CME grant requests supported by EUSA Pharma Medical Affairs please click here.

Information Leaflets

Please click here if you would like to see the summaries of the five short information leaflets designed for patients and caregivers. These can be downloaded for you provide to your patients / caregivers.

Pharmacist and Reimbursement Information

To see details of the resources for Pharmacists please click here.

Reimbursement

For any more information about obtaining Erwinaze reimbursement assistance click here.

CONTRAINDICATIONS: Hx of serious hypersensitivity to Erwinaze, including anaphylaxis; Hx of serious pancreatitis, thrombosis or hemorrhage with prior L-asparaginase therapy.

WARNINGS AND PRECAUTIONS: Discontinue if serious hypersensitivity, including anaphylaxis, OR severe or hemorrhagic pancreatitis occur. Monitor glucose (intolerance may not be reversible); With thrombosis and hemorrhage: discontinue until resolved. Use in pregnant women only if clearly needed. Do not use in lactating women.

COMMON (≥ 1%) ADVERSE REACTIONS: Serious hypersensitivity, including anaphylaxis, pancreatitis, abnormal transaminases, coagulation abnormalities, nausea, vomiting, and hyperglycemia.

Please see full Prescribing Information.

This site is only intended for residents of the United States.